Royalty Pharma News - RPRX

Company Name	Stock Ticker Symbol	Market	Type
Royalty Pharma PLC	RPRX	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.15	0.55%	27.61	18:30:04

Open Price	Low Price	High Price	Close Price	Prev Close
27.54	27.425	27.775	27.61	27.46

more quote information »

Recent News

Date	Time	Source	Heading
4/17/2024	8:00	IHNW	FeaturedGlucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring
4/17/2024	08:15	GLOBE	Royalty Pharma Declares Second Quarter 2024 Dividend
2/28/2024	16:15	GLOBE	Royalty Pharma to Present at TD Cowen’s 44th Annual Health..
2/15/2024	09:05	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/15/2024	07:33	EDGAR2	Form 8-K - Current report
2/15/2024	07:30	GLOBE	Royalty Pharma Reports Q4 and Full Year 2023 Results
2/06/2024	07:01	EDGAR2	Form 8-K - Current report
1/30/2024	16:15	GLOBE	Royalty Pharma To Announce Fourth Quarter And Full Year 2023..
1/19/2024	08:15	GLOBE	Royalty Pharma Announces Dividend Increase
1/08/2024	07:18	EDGAR2	Form 8-K - Current report
1/08/2024	07:00	GLOBE	Royalty Pharma Highlights Accomplishments and Provides..
1/03/2024	16:31	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/03/2024	16:30	EDGAR2	Form 144 - Report of proposed sale of securities
12/29/2023	16:29	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/27/2023	16:31	EDGAR2	Form 8-K - Current report
12/27/2023	13:05	EDGAR2	Form 8-K - Current report
12/19/2023	16:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	16:31	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/13/2023	16:47	EDGAR2	Form 144 - Report of proposed sale of securities
11/27/2023	16:15	GLOBE	Royalty Pharma to Present at the Evercore ISI 6th Annual..
11/16/2023	17:16	EDGAR2	Form 8-K - Current report
11/16/2023	17:13	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
11/14/2023	19:35	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/13/2023	08:10	GLOBE	Royalty Pharma and Teva Collaborate to Further Accelerate..
11/13/2023	08:00	BW	Teva and Royalty Pharma Collaborate to Further Accelerate..
11/08/2023	09:04	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/2023	07:40	EDGAR2	Form 8-K - Current report
11/08/2023	07:00	GLOBE	Royalty Pharma Reports Third Quarter 2023 Results
10/19/2023	09:29	EDGAR2	Form 8-K - Current report
10/19/2023	07:59	GLOBE	Royalty Pharma Announces Agreement to Purchase Up to $1.5..
10/16/2023	16:15	GLOBE	Royalty Pharma Declares Fourth Quarter 2023 Dividend
10/11/2023	16:15	GLOBE	Royalty Pharma To Announce Third Quarter 2023 Financial..
10/03/2023	16:15	EDGAR2	Form 144 - Report of proposed sale of securities
10/03/2023	16:15	EDGAR2	Form 144 - Report of proposed sale of securities
9/21/2023	08:25	GLOBE	Royalty Pharma Appoints Eric Schneider as Chief Technology..
9/05/2023	16:15	GLOBE	Royalty Pharma and Ascendis Pharma Enter Into $150 Million..
9/05/2023	16:01	GLOBE	Ascendis Pharma and Royalty Pharma Enter into $150 Million..
9/05/2023	08:25	GLOBE	Royalty Pharma to Present at Upcoming Investor Conferences
8/24/2023	06:30	GLOBE	Royalty Pharma and Ferring Pharmaceuticals Enter Into US..
8/24/2023	01:15	BW	Royalty Pharma and Ferring Pharmaceuticals Enter into US..
8/11/2023	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/09/2023	16:45	EDGAR2	Form 144 - Report of proposed sale of securities
8/08/2023	17:37	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/08/2023	17:36	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/08/2023	09:03	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/2023	07:31	EDGAR2	Form 8-K - Current report
8/08/2023	07:00	GLOBE	Royalty Pharma Reports Second Quarter 2023 Results
7/18/2023	16:15	GLOBE	Royalty Pharma to Announce Second Quarter 2023 Financial..
7/17/2023	16:15	GLOBE	Royalty Pharma Declares Third Quarter 2023 Dividend
7/14/2023	18:09	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/12/2023	16:47	EDGAR2	Form 144 - Report of proposed sale of securities